Indaptus Therapeutics (INDP) EBITDA (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly EBITDA of -$2.2 million for Q1 2026, up 52.77% year-over-year from -$1.4 million in Q1 2025, and up 73.52% quarter-over-quarter from -$8.2 million in Q4 2025.
Indaptus Therapeutics (INDP) EBITDA (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' EBITDA history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.
- In Q1 2026, EBITDA rose 52.77% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$17.4 million (down 8.91% YoY), while the FY2025 annual figure was -$19.8 million, down 29.08% from the prior year.
- EBITDA for Q1 2026 stood at -$2.2 million, up from -$8.2 million in the prior quarter.
- The five-year high for EBITDA was -$2.2 million in Q1 2026, with the low at -$8.2 million in Q4 2025.
- The 5-year median for EBITDA is -$4.1 million (2022), against an average of -$4.0 million.
- The sharpest annual moves came in 2022 and 2026: EBITDA plunged 631.92% in 2022, then jumped 52.77% in 2026.
- Indaptus Therapeutics' EBITDA stood at -$4.1 million in 2022, then dropped by 2.27% to -$4.2 million in 2023, then grew by 0.19% to -$4.2 million in 2024, then slumped by 95.51% to -$8.2 million in 2025, then jumped by 73.52% to -$2.2 million in 2026.
- Business Quant data shows INDP's EBITDA at -$2.2 million in Q1 2026, -$8.2 million in Q4 2025, and -$2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 133.12 Mn |
| 10 | Indaptus Therapeutics | 146.33 Mn | 134.77 Mn | - | -1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.81 Mn |
| Mar 31, 2026 | -2.16 Mn |
| Dec 31, 2025 | -8.16 Mn |
| Sep 30, 2025 | -2.65 Mn |
| Jun 30, 2025 | -4.46 Mn |
| Mar 31, 2025 | -4.57 Mn |
| Dec 31, 2024 | -4.17 Mn |
| Sep 30, 2024 | -3.14 Mn |
| Jun 30, 2024 | -4.11 Mn |
| Mar 31, 2024 | -3.94 Mn |
| Dec 31, 2023 | -4.18 Mn |
| Sep 30, 2023 | -4.25 Mn |
| Jun 30, 2023 | -3.50 Mn |
| Mar 31, 2023 | -4.46 Mn |
| Dec 31, 2022 | -4.09 Mn |
| Sep 30, 2022 | -3.55 Mn |
| Jun 30, 2022 | -3.87 Mn |
| Mar 31, 2022 | -3.40 Mn |
| Dec 31, 2021 | -3.22 Mn |
| Sep 30, 2021 | -3.37 Mn |